- Home
- IAC vs TARS Comparison
IAC vs TARS Comparison
Compare IAC & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IAC | TARS |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IAC | TARS |
|---|---|---|
| Price | $44.31 | $61.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | $46.58 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 946.9K | 429.1K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.97 | 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,365,235,000.00 | $451,360,000.00 |
| Revenue This Year | N/A | $56.43 |
| Revenue Next Year | $0.48 | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $29.56 | $38.51 |
| 52 Week High | $45.82 | $85.25 |
Technical Indicators
Market Signals| Indicator | IAC | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 70.85 | 32.55 |
| Support Level | $38.29 | $61.24 |
| Resistance Level | N/A | $76.47 |
| Average True Range (ATR) | 1.05 | 3.04 |
| MACD | 0.20 | -1.07 |
| Stochastic Oscillator | 76.05 | 11.51 |
Price Performance
Historical ComparisonAbout IAC IAC Inc.
IAC Inc is comprised of businesses including Angi Inc, Dotdash Meredith and Care.com, among many others ranging from early stage to established businesses. Its Dotdash Meredith segment consists of its Digital and Print businesses. Angi segment offers repairing and remodeling homes to cleaning and landscaping services. Care.com segment is a online destination for families to connect with caregivers for their children, aging parents, pets and homes and for caregivers to connect with families seeking care services. Search segment consists of a collection of websites providing general search services and information, and a Desktop business, which includes business-to-business partnership operations.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.